^○Yasufumi SAKAKIBARA¹, Michiko SEKIYA¹, Takashi SAITO², Takaomi C. SAIDO², Koichi M. IIJIMA¹ (1. Department of Alzheimer's Disease Research, National Center for Geriatrics and Gerontology, Aichi, Japan, 2. Laboratory of Proteolytic Neuroscience, RIKEN CBS, Saitama, Japan)

^○Tomoko TANAKA¹, Shinobu HIRAI¹, Masato HOSOKAWA², Takashi SAITO³, Takaomi SAIDO³, Masato HASEGAWA², Haruo OKADO¹ (1. Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, 2. Department of Dementia and Higher brain FUnction, Tokyo Metropolitan Institute of Medical Science, 3. Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science)

^○Daisuke JOHO¹, Takeru SUZUKI¹, Masaya FUJIWARA², Takashi SAITO³, Takaomi SAIDO³, Masaki KAKEYAMA^{1, 2, 4} (1. Lab. of Environmental Brain Science, Graduate School of Human Sciences, Waseda University, Saitama, Japan, 2. Research Institute for Environmental Medical Sciences, Waseda University, Saitama, Japan, 3. Lab. for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama, Japan, 4. Lab. of Environmental Brain Science, Faculty of Human Sciences, Waseda University, Saitama, Japan)

^○Wang FAN¹, Kyohei YAMADA¹, Kyosuke UNO^{1, 2}, Hiroshi MARUYAMA¹, Noboru MOTOYAMA², Wakako MARUYAMA³, Atsumi NITTA¹ (1. Department of pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Department of Health and Nutrition Faculty of Psycological & Physical Science Aichi Gakuin University, Aichi, Japan, 3. Laboratory of Biochemistry, Department of Human Nutrition, Sugiyama Jogakuen University, Aichi, Japan)

^○Takeru SUZUKI¹, Daisuke JOHO¹, Masaki KAKEYAMA^{1, 2, 3} (1. Lab. of Environmental Brain Science, Graduate School of Human Sciences, Waseda University, Saitama, Japan, 2. Research Institute for Environmental Medical Sciences, Waseda University, Saitama, Japan, 3. Lab. of Environmental Brain Science, Faculty of Human Sciences, Waseda University, Saitama, Japan)

^○Tomoka HATTORI¹, Haruka SAHASHI¹, Kouki HARA¹, Haruka SHIMODA¹, Yuuna SADAKA¹, Midori SODA¹, Hironao NAKAYAMA², Hiroaki MURASE³, Kiyoyuki KITAICHI¹ (1. Lab.of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan, 2. Department of Medical Science and Technology, Faculty of Health Sciences, Hiroshima International University, Higashihiroshima, Japan, 3. Glovia Co., Ltd, Tokyo, Japan)

^○Katsunori AZUMA¹, Meriem HADDAR¹, Kyousuke UNO², Shin-ichi MURAMATSU^{3, 4}, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Laboratory of molecular pharmacology faculty of pharmaceutical sciendes, University of Setsunan, Osaka, Japan, 3. Division of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan, 4. Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)